Cargando…

OR-THER-04: Long-term outcomes and reintervention of endoscopic ultrasound-guided biliary drainage for malignant biliary obstruction: A multicenter retrospective analysis of 96 cases

BACKGROUND AND OBJECTIVES: Although EUS-guided biliary drainage (EUS-BD) for malignant biliary obstruction (MBO) is increasingly reported, its long term outcomes are not fully discussed. METHODS: Consecutive patients undergoing EUS-BD for unresectable MBO were retrospectively studied. Data on recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakai, Yousuke, Ito, Yukiko, Yagioka, Hiroshi, Yamamoto, Natsuyo, Kogure, Hirofumi, Hamada, Tsuyoshi, Hakuta, Ryunosuke, Ishigaki, Kazunaga, Sato, Tatsuya, Koike, Kazuhiko, Isayama, Hiroyuki, Sasahira, Naoki, Matsubara, Saburo, Mizuno, Suguru, Takahara, Naminatsu, Saito, Kei, Takeda, Tsuyoshi, Nakamura, Tomoka, Tada, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569866/
http://dx.doi.org/10.4103/2303-9027.212266
Descripción
Sumario:BACKGROUND AND OBJECTIVES: Although EUS-guided biliary drainage (EUS-BD) for malignant biliary obstruction (MBO) is increasingly reported, its long term outcomes are not fully discussed. METHODS: Consecutive patients undergoing EUS-BD for unresectable MBO were retrospectively studied. Data on recurrent biliary obstruction (RBO) including re-intervention and other stent-related complications were extracted. RESULTS: Between Aug 2011 and Dec 2016, EUS-BD was performed in 96 patients (82 EUS-HGS and 14 EUS-CDS, 95 covered metal stent [CMS] and 1 plastic stent) at 4 tertiary referral centers. Biliary drainage prior to EUS-BD had been performed in 54%. The major causes of MBO were pancreatic cancer (52%) and biliary tract cancer (28%). Duodenal invasion (64%) and surgically altered anatomy (25%) were two major reasons for EUS-BD. Technical success rate was 98% with two technical failures (1 stent misplacement and 1 failed insertion of CMS delivery). The incidence of RBO was 36% and a median cumulative time to RBO was 6.8 months. The causes of RBO were non-tumor related (hyperplasia 17%, migration 9%, sludge 5%, reflux 2% and kink 2%), other than de novo stricture (2%). Re-intervention was successfully performed via EUS-BD route in 89% (22 stent-in-stent, 5 balloon sweep, 3 stent exchange and 1 additional antegrade stenting). Other re-interventions were 2 conversion to transpapillary stenting, 1 conversion from CDS to HGS and 1 PTBD. The incidence of other complications was 29%. CONCLUSIONS: The incidence of RBO necessitating re-interventions was not rare in EUS-BD for MBO but re-intervention via EUS-BD route was technically feasible in most cases.